Many viruses, including SARS-CoV-2, have evolved mechanisms to evade the antiviral effects of IFN, and patients with COVID-19 tend to have suppressed responses to IFN (type I, II, or III) along with impaired monocytes, macrophages, and neutrophils (35, 72, 80). This evidence concerns the gene IFNA1 and COVID-19.